Health Condition 1: I508- Other heart failure
Conditions
Interventions
Intervention1: Testosterone: 5mg testosterone gel+recommended standard therapy for chronic stable heart failure
Duration 12 week
Route - Transdermal
Control Intervention1: Recommended standard therapy
Sponsors
AIIMS Rishikesh
Eligibility
Inclusion criteria
Inclusion criteria: Male participants , >60 year age, in inpatient and outpatients, who have chronic stable heart failure irrespective of underlying etiology and whose treatment has not been modified in past 4 weeks. Chronic stable heart failure with NYHA class II or III Testosterone treatment naive patients Patients willing to provide written informed consent
Exclusion criteria
Exclusion criteria: Any contraindication to testosterone therapy Deranged Prostate specific antigen Deranged liver function Deranged renal function (serum creatinine > 1.5mg/dl) Malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in functional capacity assessment by 6 minutes walk test Change in Frailty assessment by using FRIED criteria of Frailty Phenotype Change in quality of life assessment using kansas city cardiomyopathy questionnaireTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Status of cardiac remodeling by echocardiography in the form of improved ejection fraction as a prognostic marker for disease progression Change in status of BNP level as a surrogate marker Adverse drug reaction related to testosterone transdermal patchTimepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDr Minakshi Dhar
AIIMS Rishikesh
Outcome results
None listed